Protective effect of Cnestis ferruginea and its active constituent on scopolamine-induced memory impairment in mice: A behavioral and biochemical study

Pharmaceutical Biology

Volumn 51, Issue 7, 2013, Pages 825-835

  Ishola, Ismail O ^a,b   Tota, Santoshkumar ^b   Adeyemi, Olufunmilayo O ^a   Agbaje, Esther O ^a   Narender, Tadigulopulla ^b   Shukla, Rakesh ^b  

^a UNIVERSITY OF LAGOS   (Nigeria)

^b CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Acetylcholinesterase; Amentoflavone; Amnesia; Morris water maze; Passive avoidance; Scopolamine

Indexed keywords

ACETYLCHOLINESTERASE; AMENTOFLAVONE; CNESTIS FERRUGINEA EXTRACT; NEUROPROTECTIVE AGENT; PLANT EXTRACT; SCOPOLAMINE; UNCLASSIFIED DRUG;

AMNESIA; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLINERGIC ACTIVITY; CNESTIS FERRUGINEA; CONNARACEAE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ISOLATION; DRUG MECHANISM; ENZYME ACTIVITY; MALE; MAZE TEST; MOUSE; NEUROCHEMISTRY; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PASSIVE AVOIDANCE; PHYTOCHEMISTRY; PLANT ROOT;

ACETYLCHOLINESTERASE; ADMINISTRATION, ORAL; ANIMALS; ANTIOXIDANTS; AVOIDANCE LEARNING; BIFLAVONOIDS; CHOLINESTERASE INHIBITORS; CONNARACEAE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MAZE LEARNING; MEDICINE, AFRICAN TRADITIONAL; MEMORY DISORDERS; MICE; OXIDATIVE STRESS; PLANT EXTRACTS; SCOPOLAMINE HYDROBROMIDE; TACRINE;

CONNARACEAE; MUS;

EID: 84879343560     PISSN: 13880209     EISSN: 17445116     Source Type: Journal    
DOI: 10.3109/13880209.2013.767360     Document Type: Article

References (48)

1. Agrawal R, Tyagi E, Saxena G, Nath C. (2009). Cholinergic influence on memory stages: A study on scopolamine amnesic mice. Indian J Pharmacol 41:192-6
2. Alzheimer's Association (2006). Early-Onset Dementia: A National Challenge, a Future Crisis. Washington, DC: Alzheimer's Association
3. Alzheimer's Association (2012). 2012 Alzheimer's disease, facts and figures. Available from: Www.alz.org/downloads/facts-figures- 2012.pdf [last accessed 18 Jun 2012].
4. Awasthi H, Tota S, Hanif K, et al. (2010). Protective effect of curcumin against intracerebral streptozotocin induced impairment in memory and cerebral blood flow. Life Sci 86:87-94
5. Banerjee T, Valacchi G, Ziboh VA, van der Vliet A. (2002). Inhibition of TNF-A-induced cyclooxygenase-2 expression by amentoflavone through suppression of NF-B activation in A549 cells. Mol Cell Biochem 238:105-10 (Pubitemid 35023533)
6. Beatty WW, Butters N, Janowsky DS. (1986). Patterns of memory failure after scopolamine treatment: Implications for cholinergic hypotheses of dementia. Behav Neural Biol 45:196-211 (Pubitemid 16164035)
7. Blokland A. (1995). Acetylcholine: A neurotransmitter for learning and memory? Brain Res Rev 21:285-300 (Pubitemid 26188014)
8. Bores GM, Huger FP, Petko W, et al. (1996). Pharmacological evaluation of novel Alzheimer's disease therapeutics: Acetylcholinesterase inhibitors related to galanthamine. J Pharmacol Exp Ther 277: 728-38 (Pubitemid 27168982)
9. Citron M. (2010). Alzheimer's disease: Strategies for disease modification. Nat Rev Drug Discov 9:387-98
10. Colado MI, ÓShea E, Granados R, et al. (1997). A study of the neurotoxic effect of MDMA ('ecstasy') on 5-HT neurones in the brains of mothers and neonates following administration of the drug during pregnancy. Br J Pharmacol 121:827-33 (Pubitemid 27260791)
11. Drachman DA, Leavitt J. (1974). Human memory and the cholinergic system: A relationship to aging? Arch Neurol 30:113-21
12. Dringen R. (2000). Glutathione metabolism and oxidative stress in neurodegeneration. Eur J Biochem 267:4903 (Pubitemid 30641285)
13. Ellman GL. (1959). Tissue sulfhydryl groups. Arch Biochem Biophys 82:70-7
14. El-Sherbiny DA, Khalifa AE, Attia AS, Eldenshary EES. (2003). Hypericum perforatum extract demonstrates antioxidant properties against elevated rat brain oxidative status induced by amnesic dose of scopolamine. Pharmacol Biochem Behav 76:523-33
15. Fan Y, Hu J, Li J, et al. (2005). Effect of acidic oligosaccharide sugar chain on scopolamine-induced memory impairment in rats and its related mechanisms. Neurosci Lett 374:222-6 (Pubitemid 40128300)
16. Francis PT, Palmer AM, Snape M, Wilcock GK. (1999). The cholinergic hypothesis of Alzheimer's disease: A review of progress. J Neurol Neurosurg Psychiatry 66:137-47 (Pubitemid 29103513)
17. Giacobini E. (2002). Long-Term stabilizing effect of cholinesterase inhibitors in the therapy of Alzheimer's disease. J Neural Transm Suppl 62:181-7 (Pubitemid 37046663)
18. Gilgun-Sherki Y, Melamed E, Offen D. (2002). Antioxidant treatment in Alzheimer's disease: Current state. J Mol Neurosci 21:1-11
19. Green LC, Wagner DA, Glogowski J, et al. (1982). Analysis of nitrate, nitrite, and [15N] nitrate in biological fluids. Anal Biochem 126: 131-8 (Pubitemid 13203451)
20. Guan ZZ, Zhang X, Ravid R, Nordberg A. (2000). Decreased protein levels of nicotinic receptor subunits in the hippocampus and temporal cortex of patients with Alzheimer's disease. J Neurochem 74:237-43 (Pubitemid 30012774)
21. Hebert LE, Scherr PA, Bienias JL, et al. (2003). Alzheimer disease in the U.S. population: Prevalence estimates using the 2000 Census. Arch Neurol 60:1119-22 (Pubitemid 36975801)
22. Hyman BT, Damasio H, Damasio AR, Van Hoesen GW. (1989). Alzheimer's disease. Ann Rev Public Health 10:115-40 (Pubitemid 19137975)
23. Ishola IO, Agbaje OE, Narender T, et al. (2012). Bioactivity guided isolation of analgesic and anti-inflammatory constituents of Cnestis ferruginea Vahl ex DC (Connaraceae) root. J Ethnopharmacol 142:383-9
24. Ishola IO, Akindele AJ, Adeyemi OO. (2011). Analgesic and antiinflammatory activities of Cnestis ferruginea Vahl ex DC (Connaraceae) methanol root extract. J Ethnopharmacol 135:55-62
25. Ishola IO, Ashorobi RB. (2007). Anti-stress potential of aqueous root extract of Cnestis ferruginea. Int J Pharmacol 3:295-8 (Pubitemid 351330311)
26. Jeong EJ, Lee KY, Kim SH, et al. (2008). Cognitive-enhancing and antioxidant activities of iridoid glycosides from Scrophularia buergeriana in scopolamine treated mice. Eur J Pharmacol 588: 78-84
27. Kang SS, Lee JY, Choi YK, et al. (2004). Neuroprotective effects of flavones on hydrogen peroxide-induced apoptosis in SH-SY5Y neuroblastoma cells. Bioorg Med Chem Lett 14:2261-4 (Pubitemid 38481402)
28. Kang SS, Lee JY, Choi YK, et al. (2005). Neuroprotective effects of naturally occurring biflavonoids. Bioorg Med Chem Lett 15:3588-91
29. Kopelman MD, Corn TH. (1988). Cholinergic 'blockade' as a model for cholinergic depletion. A comparison of the memory deficits with those of Alzheimer-Type dementia and the alcoholic Korsakoff syndrome. Brain 111:1079-110
30. Kulkarni KS, Kasture SB, Mengi SA. (2011). Efficacy study of Prunus amygdalus (almond) nuts in scopolamine-induced amnesia in rats. Indian J Pharmacol 42:168-73
31. Levey AI. (1996). Muscarinic acetylcholine receptor expression in memory circuits: Implications for treatment of Alzheimer disease. Proc Natl Acad Sci USA 93:13541-6 (Pubitemid 26424154)
32. Lorenzini CA, Baldi E, Bucherelli C, et al. (1996). Role of dorsal hippocampus in acquisition, consolidation and retrieval of rat's passive avoidance response: A tetrodotoxin functional inactivation study. Brain Res 730:32-9 (Pubitemid 26305321)
33. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. (1951). Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-75
34. Marcus DL, Thomas C, Rodriquez C, et al. (1998). Increased peroxidation and reduced antioxidant enzyme activity in Alzheimer's disease. Exp Neurol 150:40-4 (Pubitemid 28146421)
35. Markham KR, Sheppard C, Geiger H. (1987). 13C NMR studies on some naturally occurring amentoflavone and hinokiflavone biflavonoids. Phytochemistry 26:3335-7
36. Oke JM, Hamburger MO. (2002). Screening of some Nigerian medicinal plants for antioxidant activity using 2,2,diphenyl-picryl-hydrazyl radical. Afr J Biomed Res 5:77-9
37. Riedel W, Hogervorst E, Leboux R, et al. (1995). Caffeine attenuates scopolamine-induced memory impairment in humans. Psychopharmacol (Berl) 122:158-68 (Pubitemid 26019151)
38. Sharma D, Puri M, Tiwary AK, et al. (2010). Antiamnesic effect of stevioside in scopolamine-Treated rats. Indian J Pharmacol 42:164-7
39. Sunderland T, Tariot PN, Cohen RM, et al. (1987). Anticholinergic sensitivity in patients with dementia of the Alzheimer type and agematched controls: A dose-response study. Arch Gen Psychiatry 44:418-26 (Pubitemid 17064486)
40. Taffe MA, Weed MR, Gold LH. (1999). Scopolamine alters rhesus monkey performance on a novel neuropsychological test battery. Brain Res Cogn Brain Res 8:203-12 (Pubitemid 29518307)
41. Tota S, Awasthi H, Kamat PK, et al. (2010). Protective effect of quercetin against intracerebral streptozotocin induced reduction in cerebral blood flow and impairment of memory in mice. Behav Brain Res 209:73-9
42. Tota S, Kamat PK, Awasthi H, et al. (2009). Candesartan improves memory decline in mice: Involvement of AT1 receptors in memory deficit induced by intracerebral streptozotocin. Behav Brain Res 199:235-40
43. Tota S, Kamat PK, Shukla R, Nath C. (2011). Improvement of brain energy metabolism and cholinergic functions contributes to the beneficial effects of silibinin against streptozotocin induced memory impairment. Behav Brain Res 221:207-15
44. Wang C, Smith RL. (1975). Lowry determination of protein in the presence of Triton X-100. Anal Biochem 63:414-17
45. Whitehouse PJ, Price DL, Struble RG, et al. (1982). Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain. Science 215:1237-39 (Pubitemid 12106486)
46. WHO (2006). Traditional medicine. Available from http://www.who.int/ mediacentre/factsheets/fs134/en/ [last accessed on 29 Oct 2011].
47. Youdim KA, Spencer JP, Schroeter H, Rice-Evans C. (2002). Dietary flavonoids as potential neuroprotectants. Biol Chem 383:503-19 (Pubitemid 34506287)
48. Zhang ZJ. (2004). Therapeutic effects of herbal extracts and constituents in animal models of psychiatric disorders. Life Sci 75:1659-99